Evaluation of Pro-Inflammatory Markers IL-6 and TNF-a and their Correlation with Non-Alcoholic Fatty Liver Disease
Abstract
Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition in which excess fat accumulates in the liver of a patient with no history of alcohol abuse or other causes for secondary hepatic steatosis. The pathogenesis of NAFLD and Non-Alcoholic Steatohepatitis (NASH) has not been fully elucidated. Non-Alcoholic Fatty Liver Disease (NAFLD) consists of a complex spectrum of diseases, ranging from asymptomatic steatosis with possible aminotransferase alterations to Non-Alcoholic Steato-Hepatitis (NASH), cirrhosis, and also hepatocellular carcinoma. Pro inflammatory cytokines like IL-1, IL-6 and TNF-α play a major role in the pathogenesis of NAFLD. These cytokines also play a crucial role in the development of insulin resistance, which is a key factor in the pathogenesis of NAFLD. There is limited data on the association of IL-6 and TNF-α with NAFLD from India. Hence, we aim to assess the correlation of IL-6 and TNF-α with NAFLD.
Materials and Methods: It was a cross sectional observational study which was conducted on 40 cases of NAFLD and 40 healthy controls. All relevant investigations and serum levels of IL-6 and TNF-α were measured. Statistical analysis was done using Pearson chi-square/ fisher exact test, student t-test (un-paired). Pearson correlation test was used to see the relationship between the variables.
Result: The serum levels of IL-6 and TNF-α correlated significantly with NAFLD with a p-value of <0.001. The serum levels of IL-6 showed a significant correlation with the severity of NAFLD (p<0.001), but the same was not seen with TNF-α.
Conclusion: Our study showed significant correlation of TNF-α and IL-6 with NAFLD, which suggested a proven role of these pro-inflammatory markers in the pathogenesis of this disease as shown in past studies. In future target-based therapy is new field of research.
References
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonâ€alcoholic fatty liver disease:
Practice Guideline by the American Association for the Study of Liver Diseases, American College of
Gastroenterology and the American Gastroenterological Association. Hepatology 2012; 55(6): 2005-2023.
Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic
liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9(6): 524-530.
Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40(6): 1387-1395.
Weston SR, Leyden W, Murphy R et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with
newly diagnosed chronic liver disease. Hepatology 2005; 41(2): 372-379.
Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5-10.
Younossi ZM. Review article: current management of nonâ€alcoholic fatty liver disease and nonâ€alcoholic
steatohepatitis. Aliment Pharmacol Ther 2008; 28(1): 2-12.
Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med 2008; 19(2): 75-82.
Singh SP, Nayak S, Swain M et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern
India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004; 25(2): 76-79.
Amarapurkar D, Kamani P, Patel N et al. Prevalence of non-alcoholic fatty liver disease: population based
study. Ann Hepatol 2007; 6(3): 161-163.
Wieckowska A, Papouchado BG, Li Z et al. Increased hepatic and circulating interleukin-6 levels in human
nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103(6): 1372-1379.11. Lahsaee S, Ghazizade A, Yazdanpanah M et al. Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman. Gastroenterol Hepatol Bed Bench 2012; 5(4): 183-189.
Treeprasertsuk S, Leverage S, Adams LA et al. The Framingham risk score and heart disease in nonalcoholic
fatty liver disease. Liver Int 2012; 32(6): 945-950.
Kim SH, Lee JM, Kim JH et al. Appropriateness of a donor liver with respect to macro steatosis: application
of artificial neural networks to us images-initial experience. Radiology 2005; 234(3): 793-803.
Shannon A, Alkhouri N, Carter-Kent C et al. Ultrasonographic quantitative estimation of hepatic
steatosis in children with Nonalcoholic fatty Liver Disease (NAFLD). Journal of Pediatric Gastroenterology
and Nutrition 2011; 53(2): 190-195.
Moschen AR, Molnar C, Geiger S et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression. Gut 2010; 59(9): 1259-1264.
Hui JM, Hodge A, Farrell GC et al. Beyond insulin resistance in NASH: TNFâ€Î± or adiponectin? Hepatology
; 40(1): 46-54.
Chu CJ, Lu RH, Wang SS et al. Risk factors associated with non-alcoholic fatty liver disease in Chinese patients
and the role of tumor necrosis factor-alpha. Hepato-Gastroenterology 2006; 54(79): 2099-2102.
Tarantino G, Conca P, Pasanisi F et al. Could inflammatory markers help diagnose nonalcoholic teatohepatitis?
European Journal of Gastroenterology & Hepatology 2009; 21(5): 504-511.
Kumar R, Prakash S, Chhabra S et al. Association of pro-inflammatory cytokines, adipokines & oxidative
stress with insulin resistance & non-alcoholic fatty liver disease. Indian J Med Res 2012; 136(2): 229-236.
Paz K, Hemi R, LeRoith D et al. A Molecular Basis for Insulin Resistance elevated serine/ threonine
phosphorylation of irs-1 and irs-2 inhibits their binding to the juxta membrane region of the insulin receptor
and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272(47):
-29918.
Aguirre V, Uchida T, Yenush L et al. The c-Jun NH2-terminal kinase promotes insulin resistance during
association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 2000; 275(12):
-9054.
Cawthorn WP, Sethi JK. TNFâ€Î± and adipocyte biology. FEBS Letters 2008; 582(1): 117-131.
